). Twenty in-depth, semi-structured interviews were conducted with four stakeholders groups: 1) MSAC committee members and evaluators; 2) academic and health technology assessment experts; and 3) medical industry representatives and (iv) specialists. Interviews were digitally recorded, transcribed verbatim and coded using a constant comparative method. RESULTS: The current MSAC decision-making process was described as generally fair and transparent. However stakeholder's perceived that the burden of proof does vary from the evaluation of pharmaceuticals where "it's largely resting on the sponsor". It is perceived that the effectiveness of pharmaceuticals per se can be identified but that of medical devices and techniques has to be placed within the context of the specialist providing the service and setting. The MSAC process is described as more flexible, "intuitive" and "idiosyncratic" due to the nature of the technologies being appraised (diagnostics, devices, procedures) and the different types of applicants. Unlike pharmaceuticals these technologies are more likely to be introduced and diffused in the Australian health care system without being evaluated by MSAC. CONCLUSIONS: The results of this study suggest that stakeholder's perceived that the current process for evaluating non pharmaceutical technologies differs significantly to that of pharmaceuticals. This was thought to be partially as a result of the intrinsic differences in the items under evaluation and partially due to the different institutional arrangements under which the evaluations take place. While differences in assessment for the former reason are generally justified, differences stemming from the latter may require consideration of what constitutes best practice, and possible amendment of the process.
PHP71 A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)
Kolasa K AstraZeneca, Sodertalje, Sweden OBJECTIVES: To compare HTA recommendations of Agency for Health Technology Assessment (AHTAPoL) in Poland with HTA recommendations of the Scottish Medicines Consortium (SMC) by drug technology submitted to both Agencies for the same indication. METHODS: From 66 submissions, appraised by AHTAPol in the period January 1-December 31 2008, only drug technologies submitted to SMC for the same indication, were selected. Where there was more than one submission to a single Agency for the same indication, the most recent outcome was included. Appraisals were grouped into positive and negative recommendations. The clinical and nonclinical reasons for rejection of use were studied. The positive recommendations were divided into guidance with major, minor and without restrictions. RESULTS: Fortyeight drug technologies were appraised by both Agencies. Similar recommendations were issued in 31 cases. A contradictory guidance was given at 17 occasions. Negative recommendations constituted 40% and 25% of all HTA appraisals issued by AHTAPol and SMC respectively. While clinical reasons prevailed in Poland (14 of 19 cases), poor economic data was the most often stated reason for negative guidance in Scotland (7 of 12 cases). Positive recommendations constituted 60% and 75% of all HTA appraisals issued by AHTAPol and SMC respectively. Major restrictions prevailed in both countries: 22 of 29 and 23 of 36 in Poland and Scotland respectively. AHTAPol issued 6 recommendations with minor restrictions. There were no such cases in Scotland. At the same time, SMC issued 13 positive recommendations without restrictions.
AHTAPol generated only one such guidance. CONCLUSIONS: The positive HTA recommendations were more common in Scotland than in Poland in the group of drug technologies submitted to both Agencies for the same indication. While a clinical aspect was the most common reason for rejection in Poland, SMC pointed out mainly economic issues in their negative recommendations.
PHP72 A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND
Tilson L, O'Leary A, Usher C, Barry M National Centre for Pharmacoeconomics, Dublin, Ireland OBJECTIVES: The National Centre for Pharmacoeconomics (NCPE) appraises the cost-effectiveness of new and existing technologies (medicines, diagnostics and devices) which may entail a high budget impact to the health system, in response to requests from the Health Service Executive (HSE). In the case of new medicines, assessments may be conducted prior to reimbursement application but must be completed within 90 days. We describe the pharmacoeconomic evaluation process in Ireland and provide examples of recent appraisals and the subsequent impact on pricing and reimbursement decisions. METHODS: The pharmacoeconomic appraisals conducted by the NCPE between September 2006 and May 2009 were reviewed. The NCPE recommendations and subsequent reimbursement decisions by the HSE were recorded. The duration of the pharmacoeconomic process and the time from marketing authorisation to reimbursement was estimated. The budget impact assessments from the pharmaceutical companies were reviewed and compared for consistency. RESULTS: The NCPE conducted fourteen single technology appraisals during the study period. There is only one example of an existing medicine where cost-effectiveness data was requested to ensure continued reimbursement. All other evaluations were for newly licensed medicines. Eight of the medicines assessed were either recommended as a cost-effective use of resources or recommended with certain restrictions, and were funded by the HSE. Of the six medicines that were not considered cost-effective, two were reimbursed after a price reduction was negotiated, two were not reimbursed and the decision for the remaining two medicines is pending. The average duration of the pharmacoeconomic process was 2.7 months. The average time from marketing authorisation to reimbursement was 7 months. The review of budget impact assessments highlighted a high degree of variability between submissions. CONCLUSIONS: The findings of this review demonstrate the efficiency of the pharmacoeconomic process and the acceptance of the NCPE recommendations by the HSE for pricing and reimbursement decisions. 6 UMIT-University for Health Sciences, Hall in Tyrol, Austria, 7 University of Washington, Seattle, WA, USA OBJECTIVES: Our objective was to assess whether 15 Key Principles, previously proposed by our group-the International Working Group for HTA Advancementcould be applied to health technology assessment (HTA) programs in different jurisdictions and across a range of organizations and perspectives. METHODS: We investigated the extent to which 14 HTA organizations around the world implicitly support and implement the Key Principles. By "support," we meant that the organization backs the principle in written guidelines or other form, regardless of whether they actually follow it. By "implemented," we meant that published reports and decisions based on reports were consistent with the principles. The HTA organizations were chosen to include examples of both established and emerging entities with different roles and objectives. They include HTA organizations in Australia (PBAC), Brazil (ANVISA), Canada (CADTH), Germany (DAHTA@DIMDI, IQWiG), Korea (HIRA), Sweden (TLV, SBU), Taiwan (CDE), the UK (NICE), and United States (Blue Cross/ Blue Shield, CMS, DERP, Wellpoint). RESULTS: There is considerable variation in practices across the HTA organizations. Many of the organizations support and implement certain principles, such as being explicit about their HTA goals and scope; considering a wide range of evidence and outcomes; and seeking all available data. Other principles, such as taking a full societal perspective; having a clear system for setting priorities; explicitly characterizing uncertainty surrounding estimates; monitoring the implementation of HTA findings; and considering the generalizability and transferability of results receive much less backing. There is also variation in the degree to which organizations incorporate appropriate methods for assessing costs and benefits. CONCLUSIONS: There is considerable room for improvement for HTA organizations to adopt principles identified to reflect good HTA practices. A broader discussion is needed on principles that do not receive widespread support and implementation. Much of the research identified was of poor quality. As there was consideruch of the research identified was of poor quality. As there was considerAs there was considerable heterogeneity in the equipment studied and the testing procedures, we considered it inappropriate to pool the data for meta-analysis. Critical care devices are vulnerable evices are vulnerable to electromagnetic interferences although most clinically relevant interferences clinically relevant interferences occurred when wireless technology was used within 30 cm-1 meter of medical equipment. CONCLUSIONS: There is an urgent need for testing standardisation as well as
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PHP74 ELECTROMAGNETIC INTERFERENCES BETWEEN WIRELESS COMMUNICATION TECHNOLOGY AND CRITICAL CARE MEDICAL EQUIPMENT: A HEALTH TECHNOLOGY ASSESSMENT
There is an urgent need for testing standardisation as well as for unambiguous classification of clinically relevant electromagnetic interferences. Additionally, there is an urgent need for studies of good methodological quality to ethodological quality to inform the development of sound evidence-based policies. This study has been supported by the Spanish National I D Program (grant number STPY 1456/07).
STPY 1456/07). ).
PHP75 SCANNING THE HORIZON FOR NEW AND EMERGING OMIC TECHNOLOGIES
Benguria-Arrate G, Gutierrez-Ibarluzea I, Ibargoyen-Roteta N, Galnares-Cordero L Basque Office for Health Technology Assessment, Vitoria-Gasteiz, Araba, Spain OBJECTIVES: To analyse the processes used in the adoption of new and emerging
To analyse the processes used in the adoption of new and emerging omic or genetic technologies in the Health Systems. METHODS: We have conducted
We have conducted literature searches and have direct contact with industries producing omic technologies of our networks of experts GENTECS and SORTEK for sharing information. Furthermore, we have checked various guidelines and strategies defined to regulate the gulate the introduction of such technologies in health systems established by members of EuroScan or other agencies. RESULTS: Many omic technologies have been "on the horizon" and have shown promising results at the experimental level so are of interest to horizon scanners. But in many cases, those promising results haven't then developed into real products to be applied in the health care sector. Many factors have contributed to this failure to cross the barrier, the paradigm in the system diagnosispathology, the lack of treatment or management options and the promising sector of individualized medicine or pharmacogenetics. Different actions and initiatives established by some HTA agencies in terms of developing guidelines and rationales that could help producers and systems in the adoption of these kinds of technologies have been studied and compared. We have found some guidelines and projects that could help in the adoption of omic technologies as the GEN guideline, the National Task Force on Genomics of the European Union, and some others, and we have identify some omic technologies for the diagnosis and prognosis of different genetically complex diseases. CONCLUSIONS: New and emerging omic technologies have ew and emerging omic technologies have opened new possibilities to more accurate diagnosis and treatments; moreover they over they have provided invaluable information that could guide preventative actions on health. However, we should consider the ethical and social consequences that could be caused by implementing preventative actions based on susceptibilities and not on certainties.
PHP76 DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS INDICATOR (FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN THE RESULTS (FINANCING BIAS (FB)) OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES (EEHT)
Canon O 1 , Bueno J 2 , Oviedo E 3 , Giraldo V 2 1 Investigaciones para la salud y la equidad, Bogotá, Colombia, 2 Investigaciones para la salud y la equidad, Bogota, Colombia, 3 Universidad Nacional De Colombia, Bogota, Colombia OBJECTIVES: To propose and test an indicator (FBI) to determine the frequency of FB in the studies of EEHTs. METHODS: Using an interdisciplinary panel we propose an FB indicator (FBI) on a group of EEHT. The FBI is the probability that the results of a randomly selected paper afford economic benefits to its funder. The FBI can't be used to judge individual papers, but instead allows a comparison of FB among different sets of studies (Journals, by periods, by countries, etc). In calculating FBI the numerator is the sum of the studies that favor the funder and those omitting their source of funding; the denominator is the total papers. The test was conducted on the 2008 European EEHTs indexed in PubMed. RESULTS: We designed the FBI to estimate FB at EEHTs. We identified 88 potential EEHTs, of which 56 abstracts met the inclusion criteria, 52 of these were full papers thus submitted to analysis. Testing found: 73.07% of the papers stated the source of funding and of these, 76.31% were funded by health technologies companies, 96.55% of these papers reported results benefiting the funding company. The FBI for Europe in 2008 was 80.76%. FB decreased between the first and second half of 2008, from 81.25% to 72.22%. CON-CLUSIONS: We've presented an indicator that estimates FB probability in EEHTs. The FBI is applicable to sets of papers, it determines their FB and facilitates research control. Its systematic measurement can generate incentives to decrease FB. In order to facilitate FBI measurement it is convenient for authors to include within the abstracts: source of funding, whether the funder commercially exploits one of the comparators, whether any of the authors work for a company profiting from one of the comparators, and whether the results of the study favor the funder or the employer.
PHP77 NEW DRUGS EVALUATION IN SPAIN: THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE
Collar JM Grunenthal Pharma, S.A., Madrid, Spain OBJECTIVES: To evaluate the activity of the Joint Committee for New Drugs Evaluation (JCNDE) in Spain. Analyze the drugs evaluated since the JCNDE was founded, their scores and their potential correlation with the American CDER-FDA scores. Analyze the timings between the new drugs commercialization and its evaluation publication by the JCNDE members. METHODS: The JCNDE Standard Operation Procedures were web-based obtained. The drugs evaluations were collected gathering information from different publications and from the Regional Drug evaluating centres involved, covering the drugs evaluated for four whole years (2004) (2005) (2006) (2007) . Commercialization date in Spain were obtained from IMS database. RESULTS: Most of the 60 drugs evaluated had a high prescription potential in the Primary Care (PC) setting and were reimbursed by the Spanish National Health System. The decision algorithm has 4 key criteria to evaluate the new drugs: efficacy, safety, convenience and costs. The drugs were scored ranging from 0 (insufficient experience with the drug) to 4 (relevant therapeutic improvement). 89% of the drugs evaluated had 0-1 scores, and none of the drugs evaluated reached the maximum score. The median time of drug evaluation publication was 7 months since product launch (ranging from 7 to 51 months). Andalusia and the Basque Country have been the most active and fastest Regions to publish the JCNDE evaluations. CONCLUSIONS: The JCNDE is a valuable instrument to increase efficiency in new drugs evaluations in the PC setting. Most of the evaluations are negative and these evaluations may be the payer argument to establish drug cost containment strategies, based on the low differential efficacy of the new drugs. Although drug costs are one of the criteria to evaluate the drugs, in fact, health economics arguments are not relevant for the JCNDE. HTA recommendations were divided into positive and negative guidance. Drug technologies, appraised by HTA Agency, were classified into two groups: 1) eligible (a drug technology indicated for a prioritized health problem), and 2) not eligible (a drug technology not indicated for a prioritized health problem). RESULTS: As many as 59% and 54% of different indications were prioritized by Ministry of Health without any input from HTA process. In total, 40 negative and 43 positive HTA recommendations were issued. Only 18 of 43 (42%) drug technologies with a positive guidance were included on the reimbursement lists. At the same time as many as 6 of 40 (15%) of medicines with negative HTA recommendation were listed. In total, HTA Agency appraised 58 eligible and 25 non-eligible drug technologies. There were 32 positive HTA recommendations in the first group, of which 18 (56%) were included on the reimbursement lists. CONCLUSIONS: The HTA impact on drug reimbursement decisions in Poland is partially achieved and could be further enhanced.
PHP79 A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE
Lenderking WR United BioSource Corporation, Lexington, MA, USA OBJECTIVES: To review the use of Patient Reported Outcomes (PROs) in HTA submissions to date, with respect to the types of findings based on PROs, and the quality of the evaluations of the PRO-based evidence. METHODS: A review of the NICE website with respect to HTA appraisals that incorporated a PRO as part of the evidence base. Focus was on appraisals that departed from the 2007 reference case, and the use of the EQ-5D. RESULTS: At the time of review, 142 appraisals had been published, with 59 in progress. In particular, two case studies were identified, somatropin in growth hormone deficiency and Alzheimer's disease. In GH deficiency, QOL was the primary outcome of interest and 23 scales were evaluated across 17 RCTs. In spite of pooling and use of generic instruments, there was insufficient evidence to conclude that somatropin had an effect on quality of life (QOL). In observational study, EQ-5D results were 40% higher than disease-specific QOL-AGHDA; committee recommended use of QOL-AGHDA, and treatment guidelines that recommended treatment for fewer patients than currently being treated. In Alzheimer's, multiple scales used, but treatment benefits on QOL less clear (with donepezil for example, one study showed benefit, one was neutral, one showed worsening). CONCLUSIONS: PRO information has been incorporated in HTA appraisals, but there are significant limitations on the quality of evidence using PROs, due to study design (small sample size primarily), and lack of evidence for mapping value based on PROs.
